AUB ScholarWorks

Proapoptotic regimes for HTLV-I-transformed cells: Targeting Tax and the NF-κB pathway

Show simple item record

dc.contributor.author Kfoury Y.
dc.contributor.author Nasr R.
dc.contributor.author Hermine O.
dc.contributor.author de The H.
dc.contributor.author Bazarbachi A.
dc.contributor.editor
dc.date 5-Aug
dc.date.accessioned 2017-10-05T15:37:15Z
dc.date.available 2017-10-05T15:37:15Z
dc.date.issued 2005
dc.identifier 10.1038/sj.cdd.4401624
dc.identifier.issn 13509047
dc.identifier.uri http://hdl.handle.net/10938/15578
dc.description.abstract [No abstract available]
dc.format.extent Pages: (871-877)
dc.language English
dc.publisher LONDON
dc.relation.ispartof Publication Name: Cell Death and Differentiation; Publication Year: 2005; Volume: 12; suppl. 1; Pages: (871-877);
dc.source Scopus
dc.title Proapoptotic regimes for HTLV-I-transformed cells: Targeting Tax and the NF-κB pathway
dc.type Review
dc.contributor.affiliation Kfoury, Y., Department of Internal Medicine, American University of Beirut, PO Box 113-6044, Beirut, Lebanon
dc.contributor.affiliation Nasr, R., Department of Internal Medicine, American University of Beirut, PO Box 113-6044, Beirut, Lebanon
dc.contributor.affiliation Hermine, O., CNRS UMR 8603, Department of Hematology, Necker Hospital, Paris, France
dc.contributor.affiliation de Thé, H., UPR 9051 CNRS, Laboratoire Associé au Comité de Paris de la Ligue contre le Cancer, Hopital St. Louis, 1 Av. C. Vellefaux, 75475 Paris Cedex 10, France
dc.contributor.affiliation Bazarbachi, A., Department of Internal Medicine, American University of Beirut, PO Box 113-6044, Beirut, Lebanon
dc.contributor.authorAddress Bazarbachi, A.; Department of Internal Medicine, American University of Beirut, 1 Av. C. Vellefaux, Beirut, Lebanon; email: bazarbac@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision
dc.contributor.authorEmail dethe@chu-stlouis.fr
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Kfoury, Y
dc.contributor.authorInitials Nasr, R
dc.contributor.authorInitials Hermine, O
dc.contributor.authorInitials de The, H
dc.contributor.authorInitials Bazarbachi, A
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Bazarbachi, A (reprint author), Amer Univ Beirut, Dept Internal Med, POB 113-6044, Beirut, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016-S0305-7372(03)00081-1; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182-blood-2001-12-0372; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146-annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146-annurev.immunol.14.1.649; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126-science.2843985; Bangham CRM, 2000, CURR OPIN IMMUNOL, V12, P397, DOI 10.1016-S0952-7915(00)00107-2; Bazarbachi A, 1999, BLOOD, V93, P278; Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016-S0168-1702(01)00286-6; Bazarbachi A, 2004, CANCER RES, V64, P2039, DOI 10.1158-0008-5472.CAN-03-2390; Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016-S1470-2045(04)01608-0; BERAUD C, 1996, J ACQ IMMUN DEF SYND, V13, P76; Bex F, 1998, MOL CELL BIOL, V18, P2392; Bex F, 1997, J VIROL, V71, P3484; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084-jem.179.3.901; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006-viro.1997.8509; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128-JVI.74.5.2351-2364.2000; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Cascio P, 2002, EMBO J, V21, P2636, DOI 10.1093-emboj-21.11.2636; Chen GQ, 1996, BLOOD, V88, P1052; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016-S0092-8674(00)81064-8; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128-JVI.78.21.11823-11832.2004; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074-jbc.273.26.15891; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016-j.tcb.2004.01.004; Dewan MZ, 2003, J VIROL, V77, P5286, DOI 10.1128-JVI.77.9.5286-5294.2003; El-Sabban ME, 2002, BLOOD, V99, P3383, DOI 10.1182-blood.V99.9.3383; El-Sabban ME, 2000, BLOOD, V96, P2849; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074-jbc.M210631200; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038-sj.onc.1206468; GESSAIN A, 1985, LANCET, V2, P407; Gessain A, 1996, ADV VIRUS RES, V47, P377, DOI 10.1016-S0065-3527(08)60740-X; Good LF, 1996, J VIROL, V70, P2730; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073-pnas.86.9.3351; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074-jbc.273.39.25185; Hemelaar J, 2001, J VIROL, V75, P11106, DOI 10.1128-JVI.75.22.11106-11115.2001; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016-0092-8674(92)90083-O; Hermine O, 2004, HEMATOL J, V5, P130, DOI 10.1038-sj.thj.6200374; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146-annurev.biochem.67.1.425; HINUMA Y, 1982, GAN TO KAGAKU RYOHO, V8, P1313; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073-pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016-S0014-5793(02)03590-1; Ikeda K, 1999, INT J CANCER, V82, P599, DOI 10.1002-(SICI)1097-0215(19990812)82:4599
dc.description.citedCount 23
dc.description.citedTotWOSCount 22
dc.description.citedWOSCount 20
dc.format.extentCount 7
dc.identifier.coden CDDIE
dc.identifier.pubmedID 15846376
dc.identifier.scopusID 22744454818
dc.publisher.address MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
dc.relation.ispartOfISOAbbr Cell Death Differ.
dc.relation.ispartofPubTitle Cell Death and Differentiation
dc.relation.ispartofPubTitleAbbr Cell Death Differ.
dc.relation.ispartOfSuppl 1
dc.relation.ispartOfVolume 12
dc.source.ID WOS:000230508800006
dc.type.publication Journal
dc.subject.otherChemCAS arsenic trioxide, 1303-24-8, 1327-53-3, 13464-58-9, 15502-74-6
dc.subject.otherChemCAS bortezomib, 179324-69-7, 197730-97-5
dc.subject.otherChemCAS doxorubicin, 23214-92-8, 25316-40-9
dc.subject.otherChemCAS etoposide, 33419-42-0
dc.subject.otherChemCAS interleukin 2 receptor antibody, 179045-86-4
dc.subject.otherChemCAS retinoic acid, 302-79-4
dc.subject.otherChemCAS zidovudine, 30516-87-1
dc.subject.otherChemCAS 3-(4-methylphenylsulfonyl)-2-propenenitrile
dc.subject.otherChemCAS Antineoplastic Agents
dc.subject.otherChemCAS arsenic trioxide, 1327-53-3
dc.subject.otherChemCAS Arsenicals
dc.subject.otherChemCAS Gene Products, tax
dc.subject.otherChemCAS NF-kappa B
dc.subject.otherChemCAS Nitriles
dc.subject.otherChemCAS Oxides
dc.subject.otherChemCAS Proteasome Endopeptidase Complex, EC 3.4.25.1
dc.subject.otherChemCAS Sulfones
dc.subject.otherIndex 3 (4 methylphenylsulfonyl) 2 propenenitrile
dc.subject.otherIndex alpha interferon
dc.subject.otherIndex antineoplastic agent
dc.subject.otherIndex arsenic trioxide
dc.subject.otherIndex bortezomib
dc.subject.otherIndex doxorubicin
dc.subject.otherIndex etoposide
dc.subject.otherIndex immunoglobulin enhancer binding protein
dc.subject.otherIndex interleukin 2 receptor antibody
dc.subject.otherIndex proteasome inhibitor
dc.subject.otherIndex retinoic acid
dc.subject.otherIndex Tax protein
dc.subject.otherIndex zidovudine
dc.subject.otherIndex antineoplastic activity
dc.subject.otherIndex antiviral activity
dc.subject.otherIndex apoptosis
dc.subject.otherIndex cancer inhibition
dc.subject.otherIndex cancer resistance
dc.subject.otherIndex cell cycle
dc.subject.otherIndex clinical trial
dc.subject.otherIndex dose response
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug megadose
dc.subject.otherIndex drug potentiation
dc.subject.otherIndex drug response
dc.subject.otherIndex drug specificity
dc.subject.otherIndex drug targeting
dc.subject.otherIndex human
dc.subject.otherIndex Human T cell leukemia virus 1
dc.subject.otherIndex nonhuman
dc.subject.otherIndex priority journal
dc.subject.otherIndex prognosis
dc.subject.otherIndex protein function
dc.subject.otherIndex review
dc.subject.otherIndex sexual transmission
dc.subject.otherIndex spastic paraplegia
dc.subject.otherIndex T cell leukemia
dc.subject.otherIndex T cell lymphoma
dc.subject.otherIndex vertical transmission
dc.subject.otherIndex virus carcinogenesis
dc.subject.otherIndex virus cell transformation
dc.subject.otherIndex virus gene
dc.subject.otherIndex virus pathogenesis
dc.subject.otherIndex virus transmission
dc.subject.otherIndex Animals
dc.subject.otherIndex Antineoplastic Agents
dc.subject.otherIndex Apoptosis
dc.subject.otherIndex Arsenicals
dc.subject.otherIndex Drug Delivery Systems
dc.subject.otherIndex Gene Expression Regulation
dc.subject.otherIndex Gene Products, tax
dc.subject.otherIndex Human T-lymphotropic virus 1
dc.subject.otherIndex Humans
dc.subject.otherIndex Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated
dc.subject.otherIndex NF-kappa B
dc.subject.otherIndex Nitriles
dc.subject.otherIndex Oxides
dc.subject.otherIndex Proteasome Endopeptidase Complex
dc.subject.otherIndex Sulfones
dc.subject.otherIndex T-Lymphocytes
dc.subject.otherIndex HTLV
dc.subject.otherIndex Human T-lymphotropic virus 1
dc.subject.otherKeywordPlus VIRUS TYPE-I
dc.subject.otherKeywordPlus PROTEASOME INHIBITOR PS-341
dc.subject.otherKeywordPlus HUMAN T-CELLS
dc.subject.otherKeywordPlus TYPE-1 TAX
dc.subject.otherKeywordPlus ARSENIC TRIOXIDE
dc.subject.otherKeywordPlus LEUKEMIA-CELLS
dc.subject.otherKeywordPlus TRANSCRIPTIONAL ACTIVATION
dc.subject.otherKeywordPlus NUCLEAR TRANSLOCATION
dc.subject.otherKeywordPlus ONCOPROTEIN TAX
dc.subject.otherKeywordPlus DOWN-REGULATION
dc.subject.otherWOS Biochemistry and Molecular Biology
dc.subject.otherWOS Cell Biology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account